Erythropoietin suppresses peritoneal fibrosis in rat experimental model

Stefania Mondello, Emanuela Mazzon, Rosanna Di Paola, Concetta Crisafulli, Domenico Italiano, Michele Buemi, Calmela Aloisi, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

Abstract

Peritoneal dialysis (PD) is an alternative treatment of patients with end-stage renal disease. Unfortunately, long term peritoneal dialysis causes injury of the peritoneum associated with ultra filtration failure. Erythropoietin (EPO) is a potent stimulator of elytroid progenitor cells and its expression is enhanced by hypoxia. The aim of the present study was to evaluate the effect of EPO on the development of experimental peritoneal fibrosis induced by chlorhexidine gluconate (CG). A peritoneal fibrosis model was established using rats treated intraperitoneally with injection of CG. EPO was administered at the dose of 5000 U/kg i.p. three time per week for three weeks. When compared to CG-treated rats, EPO (5000 U/kg i.p. three time per week for three weeks) treated rats subjected to GC-induced peritoneal fibrosis experienced a significantly lower rate in the extent and severity of the histological signs of peritoneal injury. EPO also caused a substantial reduction of (i) the rise in myeloperoxidase activity (mucosa), (ii) the expression in the tissue of TNF-α, TGFβ and VEGF (iii) the increase in staining (immunohistochemistry) for nitrotyrosine and for PAR, as well as (iv) the NF-κB activation caused by CG in the peritoneum. Thus, EPO treatment reduces the degree of peritoneal fibrosis caused by CG. We propose that this evidence may help to clarify the potential therapeutic actions of EPO in patients with peritoneal fibrosis.

Original languageEnglish
Pages (from-to)138-149
Number of pages12
JournalEuropean Journal of Pharmacology
Volume604
Issue number1-3
DOIs
Publication statusPublished - Feb 14 2009

Fingerprint

Peritoneal Fibrosis
Erythropoietin
Theoretical Models
Peritoneum
Peritoneal Dialysis
Wounds and Injuries
Vascular Endothelial Growth Factor A
Peroxidase
Action Potentials
Chronic Kidney Failure
Mucous Membrane
Stem Cells
Therapeutics
Immunohistochemistry
chlorhexidine gluconate
Staining and Labeling
Injections

Keywords

  • Erythropoietin (EPO)
  • Oxidative stress
  • Peritoneal dialysis
  • Peritoneal fibrosis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mondello, S., Mazzon, E., Di Paola, R., Crisafulli, C., Italiano, D., Buemi, M., ... Cuzzocrea, S. (2009). Erythropoietin suppresses peritoneal fibrosis in rat experimental model. European Journal of Pharmacology, 604(1-3), 138-149. https://doi.org/10.1016/j.ejphar.2008.11.039

Erythropoietin suppresses peritoneal fibrosis in rat experimental model. / Mondello, Stefania; Mazzon, Emanuela; Di Paola, Rosanna; Crisafulli, Concetta; Italiano, Domenico; Buemi, Michele; Aloisi, Calmela; Cuzzocrea, Salvatore.

In: European Journal of Pharmacology, Vol. 604, No. 1-3, 14.02.2009, p. 138-149.

Research output: Contribution to journalArticle

Mondello, S, Mazzon, E, Di Paola, R, Crisafulli, C, Italiano, D, Buemi, M, Aloisi, C & Cuzzocrea, S 2009, 'Erythropoietin suppresses peritoneal fibrosis in rat experimental model', European Journal of Pharmacology, vol. 604, no. 1-3, pp. 138-149. https://doi.org/10.1016/j.ejphar.2008.11.039
Mondello, Stefania ; Mazzon, Emanuela ; Di Paola, Rosanna ; Crisafulli, Concetta ; Italiano, Domenico ; Buemi, Michele ; Aloisi, Calmela ; Cuzzocrea, Salvatore. / Erythropoietin suppresses peritoneal fibrosis in rat experimental model. In: European Journal of Pharmacology. 2009 ; Vol. 604, No. 1-3. pp. 138-149.
@article{1a58639c4a67429799a6cfe4354592b7,
title = "Erythropoietin suppresses peritoneal fibrosis in rat experimental model",
abstract = "Peritoneal dialysis (PD) is an alternative treatment of patients with end-stage renal disease. Unfortunately, long term peritoneal dialysis causes injury of the peritoneum associated with ultra filtration failure. Erythropoietin (EPO) is a potent stimulator of elytroid progenitor cells and its expression is enhanced by hypoxia. The aim of the present study was to evaluate the effect of EPO on the development of experimental peritoneal fibrosis induced by chlorhexidine gluconate (CG). A peritoneal fibrosis model was established using rats treated intraperitoneally with injection of CG. EPO was administered at the dose of 5000 U/kg i.p. three time per week for three weeks. When compared to CG-treated rats, EPO (5000 U/kg i.p. three time per week for three weeks) treated rats subjected to GC-induced peritoneal fibrosis experienced a significantly lower rate in the extent and severity of the histological signs of peritoneal injury. EPO also caused a substantial reduction of (i) the rise in myeloperoxidase activity (mucosa), (ii) the expression in the tissue of TNF-α, TGFβ and VEGF (iii) the increase in staining (immunohistochemistry) for nitrotyrosine and for PAR, as well as (iv) the NF-κB activation caused by CG in the peritoneum. Thus, EPO treatment reduces the degree of peritoneal fibrosis caused by CG. We propose that this evidence may help to clarify the potential therapeutic actions of EPO in patients with peritoneal fibrosis.",
keywords = "Erythropoietin (EPO), Oxidative stress, Peritoneal dialysis, Peritoneal fibrosis",
author = "Stefania Mondello and Emanuela Mazzon and {Di Paola}, Rosanna and Concetta Crisafulli and Domenico Italiano and Michele Buemi and Calmela Aloisi and Salvatore Cuzzocrea",
year = "2009",
month = "2",
day = "14",
doi = "10.1016/j.ejphar.2008.11.039",
language = "English",
volume = "604",
pages = "138--149",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Erythropoietin suppresses peritoneal fibrosis in rat experimental model

AU - Mondello, Stefania

AU - Mazzon, Emanuela

AU - Di Paola, Rosanna

AU - Crisafulli, Concetta

AU - Italiano, Domenico

AU - Buemi, Michele

AU - Aloisi, Calmela

AU - Cuzzocrea, Salvatore

PY - 2009/2/14

Y1 - 2009/2/14

N2 - Peritoneal dialysis (PD) is an alternative treatment of patients with end-stage renal disease. Unfortunately, long term peritoneal dialysis causes injury of the peritoneum associated with ultra filtration failure. Erythropoietin (EPO) is a potent stimulator of elytroid progenitor cells and its expression is enhanced by hypoxia. The aim of the present study was to evaluate the effect of EPO on the development of experimental peritoneal fibrosis induced by chlorhexidine gluconate (CG). A peritoneal fibrosis model was established using rats treated intraperitoneally with injection of CG. EPO was administered at the dose of 5000 U/kg i.p. three time per week for three weeks. When compared to CG-treated rats, EPO (5000 U/kg i.p. three time per week for three weeks) treated rats subjected to GC-induced peritoneal fibrosis experienced a significantly lower rate in the extent and severity of the histological signs of peritoneal injury. EPO also caused a substantial reduction of (i) the rise in myeloperoxidase activity (mucosa), (ii) the expression in the tissue of TNF-α, TGFβ and VEGF (iii) the increase in staining (immunohistochemistry) for nitrotyrosine and for PAR, as well as (iv) the NF-κB activation caused by CG in the peritoneum. Thus, EPO treatment reduces the degree of peritoneal fibrosis caused by CG. We propose that this evidence may help to clarify the potential therapeutic actions of EPO in patients with peritoneal fibrosis.

AB - Peritoneal dialysis (PD) is an alternative treatment of patients with end-stage renal disease. Unfortunately, long term peritoneal dialysis causes injury of the peritoneum associated with ultra filtration failure. Erythropoietin (EPO) is a potent stimulator of elytroid progenitor cells and its expression is enhanced by hypoxia. The aim of the present study was to evaluate the effect of EPO on the development of experimental peritoneal fibrosis induced by chlorhexidine gluconate (CG). A peritoneal fibrosis model was established using rats treated intraperitoneally with injection of CG. EPO was administered at the dose of 5000 U/kg i.p. three time per week for three weeks. When compared to CG-treated rats, EPO (5000 U/kg i.p. three time per week for three weeks) treated rats subjected to GC-induced peritoneal fibrosis experienced a significantly lower rate in the extent and severity of the histological signs of peritoneal injury. EPO also caused a substantial reduction of (i) the rise in myeloperoxidase activity (mucosa), (ii) the expression in the tissue of TNF-α, TGFβ and VEGF (iii) the increase in staining (immunohistochemistry) for nitrotyrosine and for PAR, as well as (iv) the NF-κB activation caused by CG in the peritoneum. Thus, EPO treatment reduces the degree of peritoneal fibrosis caused by CG. We propose that this evidence may help to clarify the potential therapeutic actions of EPO in patients with peritoneal fibrosis.

KW - Erythropoietin (EPO)

KW - Oxidative stress

KW - Peritoneal dialysis

KW - Peritoneal fibrosis

UR - http://www.scopus.com/inward/record.url?scp=58949095604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58949095604&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.11.039

DO - 10.1016/j.ejphar.2008.11.039

M3 - Article

C2 - 19073168

AN - SCOPUS:58949095604

VL - 604

SP - 138

EP - 149

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -